Abstract
While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Current Signal Transduction Therapy
Title: Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Volume: 1 Issue: 3
Author(s): Edith Pfitzner, Frank Nonnenmacher and Daniela Baus
Affiliation:
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Abstract: While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Export Options
About this article
Cite this article as:
Pfitzner Edith, Nonnenmacher Frank and Baus Daniela, Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226914
DOI https://dx.doi.org/10.2174/157436206778226914 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Carbon Monoxide in Renal Physiology, Pathogenesis and Treatment of Renal Disease
Current Pharmaceutical Design Looking for New Inhibitors for the Epidermal Growth Factor Receptor
Current Topics in Medicinal Chemistry Connecting A Tumor to the Environment
Current Pharmaceutical Design Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu- DOTA-Nimotuzumab
Current Radiopharmaceuticals Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Rapidly Increasing Trends in Oropharyngeal Carcinoma Assessed by Worldwide Epidemiologic Analysis
Current Cancer Therapy Reviews STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry